Male-selective effects of oxytocin agonism on alcohol intake: behavioral assessment in socially housed prairie voles and involvement of RAGE.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
03
08
2022
accepted:
25
10
2022
revised:
20
10
2022
medline:
5
5
2023
pubmed:
13
11
2022
entrez:
12
11
2022
Statut:
ppublish
Résumé
Targeting the oxytocin (OXT) peptide system has emerged as a promising new approach for the treatment of alcohol use disorder (AUD). However, further advancements in this development depend on properly modeling various complex social aspects of AUD and its treatment. Here we examined behavioral and molecular underpinnings of OXT receptor (OXTR) agonism in prairie voles, a rodent species with demonstrated translational validity for neurobiological mechanisms regulating social affiliations. To further improve translational validity of these studies, we examined effects of intranasal (IN) OXT administration in male and female prairie voles socially housed in the presence of untreated cagemates. IN OXT selectively inhibited alcohol drinking in male, but not female, animals. Further, we confirmed that exogenously administered OXT penetrates the prairie vole brain and showed that Receptor for Advanced Glycation End-products assists this penetration after IN, but not intraperitoneal (IP), OXT administration. Finally, we demonstrated that IP administration of LIT-001, a small-molecule OXTR agonist, inhibits alcohol intake in male, but not female, prairie voles socially housed in the presence of untreated cagemates. Taken together, results of this study support the promise of selectively targeting OXTR for individualized treatment of AUD.
Identifiants
pubmed: 36369481
doi: 10.1038/s41386-022-01490-3
pii: 10.1038/s41386-022-01490-3
pmc: PMC10156683
doi:
Substances chimiques
Oxytocin
50-56-6
Receptor for Advanced Glycation End Products
0
Receptors, Oxytocin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
920-928Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA025024
Pays : United States
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA019793
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA028680
Pays : United States
Organisme : NIAAA NIH HHS
ID : F31 AA028669
Pays : United States
Organisme : NIH HHS
ID : S10 OD026701
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Neuroscience. 1991;43(2-3):623-30
pubmed: 1656322
J Biol Chem. 1990 Apr 15;265(11):6098-103
pubmed: 2108152
Nat Rev Neurosci. 2016 Sep;17(9):592-9
pubmed: 27277868
Neuropsychopharmacology. 2003 Aug;28(8):1546-52
pubmed: 12813472
Physiol Behav. 2017 Oct 1;179:411-421
pubmed: 28716609
Adv Exp Med Biol. 1995;395:227-34
pubmed: 8713971
Prog Neurobiol. 2009 Jun;88(2):127-51
pubmed: 19482229
Neuron. 2012 Oct 4;76(1):142-59
pubmed: 23040812
Psychopharmacology (Berl). 2021 Mar;238(3):899-911
pubmed: 33404737
Curr Opin Neurobiol. 2018 Apr;49:132-140
pubmed: 29518698
J Addict Med. 2016 May-Jun;10(3):182-9
pubmed: 27159342
Eur J Pharmacol. 1996 Jun 3;305(1-3):39-44
pubmed: 8813529
Subst Abus. 2015;36(4):396-9
pubmed: 25259558
Psychopharmacology (Berl). 2008 Aug;199(3):403-19
pubmed: 18283437
Mod Pathol. 2005 Oct;18(10):1385-96
pubmed: 15933755
Neuropharmacology. 2019 Jan;144:301-311
pubmed: 30399367
Psychopharmacology (Berl). 1992;106(4):439-46
pubmed: 1579619
Sci Rep. 2020 Feb 20;10(1):3017
pubmed: 32080303
Pharmacol Rev. 1975 Sep;27(3):357-65
pubmed: 817307
Mol Psychiatry. 2018 Jan;23(1):115-122
pubmed: 28289281
Biochem J. 2003 Mar 15;370(Pt 3):1097-109
pubmed: 12495433
Nat Commun. 2020 Jun 3;11(1):2783
pubmed: 32494001
Addict Biol. 2021 Mar;26(2):e12893
pubmed: 32160654
Neurosci Biobehav Rev. 2020 Mar;110:3-27
pubmed: 30179633
Alcohol Clin Exp Res. 2013 Mar;37(3):484-9
pubmed: 23025690
Commun Biol. 2020 Feb 13;3(1):70
pubmed: 32054984
J Neurosci. 2009 Feb 18;29(7):2259-71
pubmed: 19228979
Sci Rep. 2013 Dec 06;3:3440
pubmed: 24310737
Sci Rep. 2018 May 29;8(1):8201
pubmed: 29844336
J Clin Pharmacol. 2017 Dec;57(12):1573-1581
pubmed: 28679021
Int Rev Neurobiol. 2016;126:403-21
pubmed: 27055620
Int Rev Neurobiol. 2018;140:201-247
pubmed: 30193705
Pharmacol Ther. 2021 Jul;223:107820
pubmed: 33600854
Addict Biol. 2021 Mar;26(2):e12945
pubmed: 32761675
Neuroscience. 1997 May;78(2):499-509
pubmed: 9145805
Pharmacol Biochem Behav. 2017 Sep;160:14-20
pubmed: 28778739
Brain Res Mol Brain Res. 1991 Mar;9(4):293-8
pubmed: 1645432
J Med Chem. 2018 Oct 11;61(19):8670-8692
pubmed: 30199637
PLoS Biol. 2019 Apr 16;17(4):e2006421
pubmed: 30990816
Pharmacol Biochem Behav. 2014 Apr;119:39-48
pubmed: 23916423
Neuroscience. 2005;135(1):147-54
pubmed: 16084653
Biochem J. 2006 May 15;396(1):109-15
pubmed: 16503878
Nat Commun. 2017 Dec 13;8(1):2102
pubmed: 29235461
Biol Psychiatry. 2016 Feb 1;79(3):194-202
pubmed: 26321019
Arch Gen Psychiatry. 1992 Nov;49(11):876-80
pubmed: 1345133
Neuropsychopharmacology. 2018 May;43(6):1235-1246
pubmed: 29090683
Commun Biol. 2019 Feb 25;2:76
pubmed: 30820471
Horm Behav. 2016 Mar;79:8-17
pubmed: 26643557
Addict Biol. 2011 Jan;16(1):92-107
pubmed: 20579002
JAMA. 1986 Sep 19;256(11):1449-55
pubmed: 3528541
Neuroendocrinology. 1986;44(4):415-21
pubmed: 3029614
Behav Brain Res. 2007 Jan 10;176(1):170-86
pubmed: 17000015
Addict Biol. 2013 Nov;18(6):937-46
pubmed: 23231446
Pharmacogenetics. 1997 Jun;7(3):223-33
pubmed: 9241662
Bioorg Med Chem Lett. 2004 Sep 6;14(17):4585-9
pubmed: 15357997
Ann N Y Acad Sci. 1992 Jun 12;652:29-38
pubmed: 1320828
Horm Behav. 2012 Mar;61(3):331-9
pubmed: 22198308
Pharmacol Biochem Behav. 2016 Jan;140:27-32
pubmed: 26519603
Neuropsychopharmacology. 2021 Oct;46(11):1950-1957
pubmed: 34127796
Pharmacol Res. 2019 Aug;146:104324
pubmed: 31238093
Neuroendocrinology. 1997 Jan;65(1):9-17
pubmed: 9032770
Sci Rep. 2017 Dec 8;7(1):17222
pubmed: 29222505
Soc Neurosci. 2018 Dec;13(6):710-717
pubmed: 29564972
Addiction. 2002 Mar;97(3):347-56
pubmed: 11964111
Trends Endocrinol Metab. 2003 Jul;14(5):222-7
pubmed: 12826328
J Cereb Blood Flow Metab. 1985 Sep;5(3):350-7
pubmed: 3897253
Alcohol Alcohol. 2019 Jul 1;54(4):353-360
pubmed: 31062856
J Med Chem. 2017 Sep 14;60(17):7213-7232
pubmed: 28482155
Neurosci Lett. 2006 Feb 13;394(2):146-51
pubmed: 16289323
Psychoneuroendocrinology. 2013 Oct;38(10):1985-93
pubmed: 23579082
Int J Mol Sci. 2021 Nov 08;22(21):
pubmed: 34769501
Front Psychiatry. 2017 Nov 17;8:226
pubmed: 29204125
J Neurosci. 2015 Nov 25;35(47):15696-701
pubmed: 26609161
Endocrinology. 1995 Nov;136(11):5135-8
pubmed: 7588251
Mol Pharm. 2018 Mar 5;15(3):1105-1111
pubmed: 29338251
Alcohol Clin Exp Res. 2017 May;41(5):955-964
pubmed: 28212464
Front Pharmacol. 2013 Jul 04;4:84
pubmed: 23847535